top of page


  1. Ommen, SR, Mital, S, Burke, MA, 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:e558–e631. doi: 10.1161/ CIR.0000000000000937

  2. Semsarian, JI, Ingles, J, Maron, MS, New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2015; 65: 1249-64.

  3. Maron MS, Hellawell JL, Lucove JC, et al. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016;117:1651–4. DOI: 10.1016/j.amjcard.2016.02.044

  4. Maron BJ, Rowin EJ, Casey SA, et al. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol. 2016;1:98–105. doi:10.1001/jamacardio.2015.0354

  5. Maron, BJ, Maron, MS, Rowin, EG. Perspectives on the overall risks of living with hypertrophic cardiomyopathy. Circulation. 2017;135:2317–2319.

  6. Marian, AJ, Braunwald, E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research. 2017;121:749–770.

  7. Maron, BJ, Rowin, EJ, Maron, MS. Global Burden of Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;5:376-8. DOI: 10.1016/j.jchf.2018.03.004

  8. Ingles, J, Burns, C, Bagnall, RD, Nonfamiliar Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017;10:e001620.

  9. Ho, CY, Day, SM, Ashley, EA, Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138:1387–1398. DOI: 10.1161/CIRCULATIONAHA.117.033200

  10. MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb. CAMZYOSTM (mavacamten): US prescribing information. 2022.

  11. Spertus, JA, Fine, JT, Elliott, P, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 May 21; 397(10293):2467-2475.

  12. Keam, S.J. Mavacamten: First Approval. Drugs 82, 1127–1135 (2022).

  13. Nguyen A, Schaff HV. Surgical Myectomy: Subaortic, Midventricular, and Apical. Cardiol Clin. 2019 Feb;37(1):95-104. PMID: 3044772014.

  14. Shah AA, Glower DD, Gaca JG. Trans-aortic Alfieri stitch at the time of septal myectomy for hypertrophic obstructive cardiomypopathy. J Card Surg. 2016;31:503-506. PMID: 27401021

bottom of page